| Original language | English |
|---|---|
| Pages (from-to) | 316-318 |
| Number of pages | 3 |
| Journal | Journal of Neurology, Neurosurgery and Psychiatry |
| Volume | 89 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2018 |
| Externally published | Yes |
Funding
| Funders | Funder number |
|---|---|
| Italian Ministry of Health and Fondazione Italiana | |
| Ministry of science, republic of serbia | 175031 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 89, No. 3, 03.2018, p. 316-318.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Diagnosis of multiple sclerosis
T2 - A multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria
AU - Preziosa, Paolo
AU - Rocca, Maria A.
AU - Mesaros, Sarlota
AU - Meani, Alessandro
AU - Montalban, Xavier
AU - Drulovic, Jelena
AU - Droby, Amgad
AU - Zipp, Frauke
AU - Calabrese, Massimiliano
AU - Sastre-Garriga, Jaume
AU - Dujmovic-Basuroski, Irena
AU - Rovira, Alex
AU - Filippi, Massimo
N1 - Funding Information: competing interests PP has received speakers honoraria from Biogen Idec, Novartis and exceMeD. MAr has received speakers honoraria from Biogen Idec, Novartis, Genzyme, sanofi-Aventis, teva and Merk serono and receives research support from the Italian Ministry of Health and Fondazione Italiana sclerosi Multipla. XM has received speaking honoraria and travel expenses for participation in scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Actelion, Bayer, Biogen, Celgene, Genzyme, Merck, Novartis, Oryzon Genomics, roche, sanofi-Genzyme and teva Pharmaceutical. FZ received funds for consultation or research/symposia from Novartis, Merck serono, teva, Ono, Octapharma, Biogen, Genzyme and sanofi Aventis. MC received funds for consultation or research/symposia from Novartis, Merck serono, teva, Biogen, Genzyme and sanofi Aventis. Js-G has received compensation in the last 12 months for participating on advisory boards, speaking, travel expenses for scientific meetings or research support from Genzyme, Novartis, Biogen, excemed and Merck. Ar serves on scientific advisory boards for Biogen Idec, Novartis, sanofi-Genzyme, and OLeA Medical; has received speaker honoraria from exceMeD Bayer, Genzyme, sanofi-Aventis, Bracco, Merck-serono, teva Pharmaceutical Industries Ltd, OLeA Medical, stendhal, Novartis and Biogen Idec; and has research agreements with siemens AG and Icometrix. MF is editor-in-Chief of the Journal of Neurology; serves on a scientific advisory board for teva Pharmaceutical Industries; has received compensation for consulting services and/or speaking activities from Biogen Idec, Merk-serono, Novartis, and teva Pharmaceutical Industries; and receives research support from Biogen Idec, teva Pharmaceutical Industries, Novartis, Italian Ministry of Health, Fondazione Italiana sclerosi Multipla (FIsM), Cure PsP, Alzheimer’s Drug Discovery Foundation (ADDF), the Jacques and Gloria Gossweiler Foundation (switzerland), and ArisLA (Fondazione Italiana di ricerca per la sLA). Funding Information: Funding this study was partially supported by a grant from the Ministry of science, republic of serbia (project number 175031).
PY - 2018/3
Y1 - 2018/3
UR - https://www.scopus.com/pages/publications/85041755728
U2 - 10.1136/jnnp-2017-315863
DO - 10.1136/jnnp-2017-315863
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???
C2 - 28724720
AN - SCOPUS:85041755728
SN - 0022-3050
VL - 89
SP - 316
EP - 318
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 3
ER -